Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-8807

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-8807). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298807)

Label for Rivastigmine Transdermal System patch, extended release, 9.5 mg/24 hours strength by Bryant Ranch Prepack. The label includes storage instructions, usage directions, and warnings. It also displays the NDC 63629-8807, a barcode, and indicates the package contains 30 systems, Rx only.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure diagram showing the molecular structure of rivastigmine, the active ingredient in Rivastigmine Transdermal System 9.5 mg/24h extended-release patch by Bryant Ranch Prepack.*

FDA Label Image

Figure 1 (Rivastigmine 02)

An illustration showing a cross-sectional view of a transdermal patch for Rivastigmine Transdermal System 9.5 mg/24h. The diagram details four distinct layers of the patch with two dimples indicated on the bottom surface, likely for application or adhesion purposes.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A line graph depicting plasma rivastigmine concentration (ng/mL) over 24 hours with three dosage strengths of rivastigmine transdermal system: 13.3 mg/24h, 9.5 mg/24h, and 4.6 mg/24h. The graph shows rivastigmine levels increasing after application, peaking between 4 and 8 hours, then gradually declining through 24 hours. Different markers (triangle, circle, and filled circle) represent each dosage group with sample sizes indicated (n=19, 22, and 22, respectively). Error bars indicate variability in measurements.*

FDA Label Image

Figure 3 (Rivastigmine 04)

A line graph showing least square mean changes (+/- SEM) from baseline ADAS-cog ratings over 24 weeks of treatment. It compares clinical improvement and decline for Rivastigmine Transdermal System 17.4 mg/24 hours, 9.5 mg/24 hours, oral capsules 6 mg BID, and placebo. The graph illustrates that higher dose patches show more clinical improvement compared to capsules and placebo over time.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A bar chart displaying percentage of patients by ADCS-CGIC rating categories, comparing four groups: 17.4 mg/24 hours, 9.5 mg/24 hours, Capsules 6 mg BID, and Placebo. Ratings range from Markedly Improved to Markedly Worse, with the highest percentages observed in the No Change category across the groups.*

FDA Label Image

Figure 5 (Rivastigmine 06)

Line graph showing ADCS-ADL change from baseline over 48 weeks of treatment comparing Rivastigmine Transdermal System 13.3 mg/24hr and 9.5 mg/24hr. The vertical axis represents change from baseline, with clinical improvement upward and decline downward. Both dosages show decreasing ADCS-ADL scores over time, with the 9.5 mg/24hr group declining more steeply.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A line graph showing ADAS-Cog change from baseline (least squares means and standard error of the mean) over 48 weeks of treatment for Rivastigmine Transdermal System at doses of 13.3 mg/24 hr and 9.5 mg/24 hr. The y-axis measures cognitive change from clinical improvement to clinical decline, while the x-axis shows weeks of treatment. The graph compares the effects of the two doses over time with error bars indicating variability.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph depicting least squares mean change over 24 weeks of treatment comparing two sizes of Rivastigmine Transdermal System patches, 15 cm² and 5 cm². The y-axis shows LS mean change from baseline (range approximately -7.5 to 3.0), and the x-axis shows weeks of treatment (0, 8, 16, 24). The 15 cm² patch shows mean changes near zero with slight fluctuations, indicating clinical stability, while the 5 cm² patch shows progressively declining mean scores, indicating clinical decline. Error bars represent standard errors. Statistical significance is noted at weeks 16 and 24 for the 15 cm² patch.*

FDA Label Image

Figure 8 (Rivastigmine 09)

A line chart comparing least squares mean changes over 24 weeks of treatment between Rivastigmine Transdermal System 15 cm² and 5 cm² patches. The y-axis represents LS mean change with standard errors, from clinical improvement to decline, and the x-axis shows weeks of treatment at 0, 8, 16, and 24 weeks. Statistical significance values are indicated at 16 and 24 weeks.*

FDA Label Image

Figure A (Rivastigmine 10)

Illustration showing the components of the Rivastigmine Transdermal System patch. The diagram includes the pouch packaging, the transdermal patch labeled with Rivastigmine and protective liners, and a detailed view of the patch's adhesive side with medicine and outside backing. The image explains the protective liners and structure of the patch system.*

FDA Label Image

Figure B (Rivastigmine 11)

Illustration showing possible application sites for the Rivastigmine Transdermal System 9.5 mg/24h patch. Indicates placement options on the left or right upper arm (side view), left or right side of chest (front view), left or right upper back, and left or right lower back (back views). Each site is marked with a shaded rectangular area representing the patch position.*

FDA Label Image

Figure C (Rivastigmine 12)

Illustration showing a hand holding a Bryant Ranch Prepack Rivastigmine Transdermal System patch packet labeled with 9.5 mg/24h strength. The patch is shown partially behind a pair of scissors, indicating opening or cutting the pouch to access the transdermal system.*

FDA Label Image

Figure D (Rivastigmine 13)

An instructional illustration showing a close-up of hands peeling protective liners from the sticky surface of a Rivastigmine transdermal patch to prepare it for application on the skin.*

FDA Label Image

Figure E (Rivastigmine 14)

An instructional diagram showing the application of a Rivastigmine Transdermal System patch to the upper back of a person. One hand is holding the patch while the other hand presses it against the skin to affix it securely.*

FDA Label Image

Figure F (Rivastigmine 15)

An instructional illustration showing the upper back area of a person with a hand positioned to apply a transdermal patch. The image demonstrates placement of the Rivastigmine Transdermal System patch on the back.*

FDA Label Image

Figure G (Rivastigmine 16)

An instructional illustration depicting the application of a Rivastigmine Transdermal System patch to the upper chest. One hand is shown holding the patch while the other hand is smoothing it onto the skin in a circular motion, demonstrating proper placement and adhesion technique.*

FDA Label Image

Figure H (Rivastigmine 17)

An instructional three-part illustration showing how to safely dispose of a used Rivastigmine Transdermal System patch, 9.5 mg/24h. The first panel shows folding the sticky sides of the patch together. The second panel demonstrates sliding the folded patch into an empty pouch. The third panel depicts placing the pouch in the trash, with a reminder to keep it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.